Achromobacter xylosoxidans infection and resistance monitoring in adult cystic fibrosis patients
DOI: 10.32364/2587-6821-2021-5-7-462-467
V.R. Makhmutova1, T.E. Gembitskaya2, A.G. Chermensky2, O.N. Titova2, N.A. Kuzubova2
1Multidisciplinary Сity Hospital No. 2, St. Petersburg, Russian Federation
2I.P. Pavlov First St. Petersburg State Medical University, St. Petersburg, Russian Federation
Aim: to evaluate the infection rate and resistance of isolated Achromobacter xylosoxidans to carbapenems in adult cystic fibrosis patients (CF).
Patients and Methods: a retrospective analysis of the results of culture test and time-of-flight mass spectrometry MALDI-TOF was conducted: 685 sputum samples of 58 adult CF patients for a period of 5 years (2016–2020). To assess the sensitivity to imipenem and meropenem, the agar gradient diffusion and disk diffusion method were used.
Results: the incidence of infection with A. xylosoxidans in adult CF patients for the period from 2016 to 2020 when monitoring a single sample of patients (n=24) to evaluate the occurrence of this pathogen with increasing age ranged from 16.6% in 2016–2017, increasing to 37.5% in 2018–2019, and with a further reduction to 20.8% (associated with disease fatal outcome in 3 of the 9 infected patients). There was no statistically significant dependence of the fatal outcome on infection with A. xylosoxidans. When analyzing the entire pool of patients (n=58) from 2016 to 2020, the release frequency of Pseudomonas aeruginosa remains approximately the same, varying from 63.3% to 46.5% and maintaining a numerical advantage in all follow-up periods, while the A. xylosoxidans infection ranges from 13.7% to 39.3%. In 2016–2018, 50% of isolates were sensitive to carbapenems, in 2018 — 53.8% of isolates, in 2019–2020 — the activity of obtained isolates decreased to 37.5% and 30.7%, respectively.
Conclusion: despite the dynamics of indicators and the sample size, the dynamics over 5 years maintained a group-wide proportion of microbiome species dominated primarily by Pseudomonas infection and A. xylosoxidans. In our follow-up, the activity of carbapenems in relation to A. xylosoxidans has almost halved.
Keywords: cystic fibrosis, Burkholderia cepacia complex, Achromobacter xylosoxidans, Pseudomonas aeruginosa, lethality, antibiotic resistance, carbapenems.
For citation: Makhmutova V.R., Gembitskaya T.E., Chermensky A.G. et al. Achromobacter xylosoxidans infection and resistance monitoring in adult cystic fibrosis patients. Russian Medical Inquiry. 2021;5(7):462–467 (in Russ.). DOI: 10.32364/2587-6821-2021-5-7-462-467.
2. Lambiase A., Raia V., Stefani S. et al. Burkholderia cepacia complex infection in a cohort of Italian patients with cystic fibrosis. J Microbiol. 2007;45(3):275–279.
3. Klinger J.D., Thomassen M.J. Occurrence and antimicrobial susceptibility of gram-negative nonfermentative bacilli in cystic fibrosis patients. Diagn Microbiol Infect Dis. 1985;3(2):149–158.
4. Chernukha M.Yu., Shaginyan I.A., Zhukhovitsky V.G. and others. Application of the MALDI Biotyper system and the microbiological diagnostic algorithm for the identification of non-fermenting microorganisms isolated from the respiratory tract in patients with cystic fibrosis. Clinical microbiology and antimicrobial chemotherapy. 2017;19(4):327–334 (in Russ.).
5. National Consensus (2nd Edition) Cystic Fibrosis: Definition, Diagnostic Criteria, Therapy. Edited by E.I. Kondratyeva, N.Yu. Kashirskaya, N.I. Kapranova. M.: LLC "Company BORGES"; 2018 (in Russ.).
6. Krasovsky S.A., Nikonova V.S., Kashirskaya N.Yu. and other. Clinical-genetic, microbiological and functional characteristics of patients with cystic fibrosis living in Moscow and the Moscow region. Voprosy sovremennoy pediatrii. 2013;12(1):24–30 (in Russ.).
7. Lobo L.J., Tulu Z., Aris R.M., Noone P.G. Pan-Resistant Achromobacter xylosoxidans and Stenotrophomonas maltophilia Infection in Cystic Fibrosis Does Not Reduce Survival After Lung Transplantation. Transplantation. 2015;99(10):2196–2202. DOI: 10.1097/TP.0000000000000709.
8. Trancassini M., Iebba V., Citerà N. et al. Outbreak of Achromobacter xylosoxidans in an Italian Cystic fibrosis center: genome variability, biofilm production, antibiotic resistance, and motility in isolated strains. Front Microbiol. 2014;5:138. DOI: 10.3389/fmicb.2014.00138.
9. Green H., Jones A.M. The microbiome and emerging pathogens in cystic fibrosis and non-cystic fibrosis bronchiectasis. Semin Respir Crit Care Med. 2015;36(2):225–235. DOI: 10.1055/s-0035-1546752.
10. Kerem E., Conway S., Elborn S. et al. Standards of care for patients with cystic fibrosis: a European consensus. J Cyst Fibros. 2005;4(1):7–26. DOI: 10.1016/j.jcf.2004.12.00.
11. MU 4.2.2039–05 "Technique for collecting and transporting biomaterials to microbiological laboratories". (Electronic resource.) URL: https://www.rospotrebnadzor.ru/documents/details.php?ELEMENT_ID=4750 (access date: 12.07.2021) (in Russ.).
12. SP 1.2.036–95 "Procedure for accounting, storage, transfer and transportation of microorganisms of I-IV pathogenicity groups". (Electronic resource.) URL: http://docs.cntd.ru/document/901799960 (access date: 12.05.2020) (in Russ.).
13. Chernukha M.Yu., Avetisyan L.R., Shaginyan I.A. et al. Algorithm for microbiological diagnosis of chronic lung infection in patients with cystic fibrosis. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2014;16(4):276–290 (in Russ.).
14. Clinical guidelines. Determination of the sensitivity of microorganisms to antimicrobial drugs (2018). (Electronic resource.) URL: http://www.antibiotic.ru/minzdrav/clinical-recommendations/ (access date: 12.07.2021).
15. Register of patients with cystic fibrosis in the Russian Federation. 2019. Ed. N.Yu. Kashirskaya, E.I. Kondratyeva, S.A. Krasovsky et al.. M.: Publishing House "Medpractica-M"; 2021 (in Russ.).
16. Krasovsky S.A., Amelina E.L., Kashirskaya N.Yu. et al. Dynamics of indicators of the national register of patients with cystic fibrosis for 2011–2017. Sibirskoye meditsinskoye obozreniye. 2019;2(116):14–18 (in Russ.). DOI: 10.20333 / 2500136-2019-2-14-18.
17. Raso T., Bianco O., Grosso B. et al. Achromobacter xylosoxidans respiratory tract infections in cystic fibrosis patients. APMIS. 2008;116(9):837–841. DOI: 10.1111/j.1600-0463.2008.00995.x.
18. Gabrielaite M., Bartell J.A., Nørskov-Lauritsen N. et al. Transmission and Antibiotic Resistance of Achromobacter in Cystic Fibrosis. J Clin Microbiol. 2021;59(4):02911–20. DOI: 10.1128/JCM.02911-20.
19. Tan K., Conway S.P., Brownlee K.G. et al. Alcaligenes infection in cystic fibrosis. Pediatr Pulmonol. 2002;34(2):101–104. DOI: 10.1002/ppul.10143.
20. Corriveau S., Sykes J., Stephenson A.L. Cystic fibrosis survival: the changing epidemiology. Curr Opin Pulm Med. 2018;24(6):574–578. DOI: 10.1097/MCP.0000000000000520.
21. Magni A., Trancassini M., Varesi P. et al. Achromobacter xylosoxidans genomic characterization and correlation of randomly amplified polymorphic DNA profiles with relevant clinical features of cystic fibrosis patients. J Clin Microbiol. 2010;48(4):1035–1039. DOI: 10.1128/JCM.02060-09.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
